Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

Phase 3positiveEnvudeucitinibPositive

AI Analysis

Summary

Envudeucitinib Phase 3 long-term data for plaque psoriasis achieved the highest reported PASI 100 skin clearance among oral therapies, positioning it as a potential new standard treatment.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Highest reported PASI 100 skin clearance among oral therapies

Importance:7/10

Sentiment:

0.80

Phase 3plaque psoriasisoral therapyPASI 100long-term data

Read the original article

Published by GlobeNewswire Clinical Studies on August 10, 2026 8:05 PM

Read Original